Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-small Cell Lung Cancer (FALCON)

This study has been completed.
Information provided by (Responsible Party):
OXiGENE Identifier:
First received: March 18, 2008
Last updated: April 4, 2014
Last verified: April 2014

The purpose of this study is to determine the safety, tolerability and efficacy of combretastatin A4 phosphate (CA4P), also known as fosbretabulin, in combination with bevacizumab (Avastin), carboplatin and paclitaxel in patients with chemotherapy naïve non-small cell lung cancer (NSCLC). This is a randomized parallel arm study. All participants will receive carboplatin, paclitaxel and bevacizumab, and half will additionally receive CA4P. Patients who complete the first 6 cycles of therapy and have not experienced disease progression will receive maintenance therapy with bevacizumab alone or with bevacizumab plus CA4P.

The rationale for this study is the potential additive or synergistic actions of vascular disrupting agents like CA4P with anti-angiogenic agents like bevacizumab.

Condition Intervention Phase
Drug: fosbretabulin, CA4P
Drug: Carboplatin
Drug: Bevacizumab
Drug: Paclitaxel
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Study to Assess the Safety and Efficacy of Carboplatin, Paclitaxel and Bevacizumab ± Combretastatin A4 Phosphate (CA4P) Followed by Bevacizumab ± CA4P in Subjects With Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)

Resource links provided by NLM:

Further study details as provided by OXiGENE:

Primary Outcome Measures:
  • Safety and tolerability of the combination therapy assessed by analysis of adverse events, physical examination, blood tests, ECGs [ Time Frame: Six 21-day cycles ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Tumor response rate as determined from tumor imaging by CT scan [ Time Frame: Six 21-day cycles ] [ Designated as safety issue: Yes ]
  • Overall Survival [ Time Frame: Until death ] [ Designated as safety issue: Yes ]

Enrollment: 63
Study Start Date: March 2008
Study Completion Date: October 2011
Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Arm 1: Chemotherapy+bevacizumab
Carboplatin, paclitaxel, and bevacizumab administered intravenously Day 1 every 3 weeks for up to six treatment cycles. After 6 cycles, subjects who have not progressed may continue to receive bevicizumab alone on Day 1 every 3 weeks until progression or until 12 months from randomization.
Drug: Carboplatin
Carboplatin (AUC 6) on Day 1 of each 21 day cycle for 6 cycles.
Other Name: Paraplatin
Drug: Bevacizumab
Bevacizumab (15 mg/kg) on Day 1 of each 21 day cycle for 6 cycles.
Other Name: Avastin
Drug: Paclitaxel
Paclitaxel 20 mg/m sq will be administered on Day 1 of six 21-day cycles
Other Name: Taxol
Experimental: Arm 2: Comparator regimen + fosbretabulin, CA4P
Carboplatin (AUC 6), paclitaxel (200 mg/m2), and bevacizumab (15 mg/kg),administered intravenously Day 1 with and CA4P (60 mg/m2) on Days 7, 14, and 21 every 3 weeks for up to six treatment cycles. After 6 cycles, subjects who have not progressed may continue to receive bevacizumab on Day 1 and CA4P on Days 1, 7 and 14 every 3 weeks until progression or until 12 months from randomization.
Drug: fosbretabulin, CA4P
Arm 2 only: CA4P(60 mg/meter sq) on Days 7,14 and 21 for 6 cycles.
Other Names:
  • fosbretabulin
  • combretastatin
  • Zybrestat
Drug: Carboplatin
Carboplatin (AUC 6) on Day 1 of each 21 day cycle for 6 cycles.
Other Name: Paraplatin
Drug: Bevacizumab
Bevacizumab (15 mg/kg) on Day 1 of each 21 day cycle for 6 cycles.
Other Name: Avastin
Drug: Paclitaxel
Paclitaxel 20 mg/m sq will be administered on Day 1 of six 21-day cycles
Other Name: Taxol

Detailed Description:

Lung cancer has become the leading cause of cancer death in both men and women in the US and Europe, accounting for 29% of all cancer deaths. Non-Small Cell Lung cancer (NSCLC) accounts for approximately 80% of all lung cancer cases. Currently, no curative treatment is available for advanced stages of the disease (stages III and IV), which comprise the majority of cases. Treatment with the combination of carboplatin and paclitaxel has been shown to be effective and well tolerated in advanced stage NSCLC. Targeted therapies, such as bevacizumab, often act synergistically with chemotherapy. Bevacizumab inhibits VEGF, necessary for endothelial cell proliferation and new blood vessel formation. CA4P targets existing abnormal vasculature of tumors, impeding tumor blood flow and leading to extensive tumor cell death as a consequence of oxygen and nutrient deprivation.

This study will compare the effect of CA4P when combined with chemotherapy and bevacizumab on progression free survival (PFS) to PFS after chemotherapy and bevacizumab alone.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Pathologically confirmed Stage IIIB NSCLC with malignant pleural effusion, or Stage IV disease
  • Measurable disease on CT scan (by the RECIST criteria)
  • Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or 1 (which means able to independently care for self and to perform light work) .
  • Adequate blood counts
  • Adequate liver and kidney function
  • Subjects or their legal representatives must be able to read, understand and provide written informed consent to participate in the trial.

Exclusion Criteria:

  • Predominant Squamous Cell NSCLC histology.
  • History of treatment for NSCLC with chemotherapy, biological therapy, immunotherapy (surgery or radiation therapy are accepted)
  • Brain (CNS) metastasis by head CT scan or MRI
  • Subjects with history of prior malignancy except for curatively treated basal cell carcinoma of the skin; cervical intra-epithelial neoplasia; or localized prostate cancer with a current prostate specific antigen (PSA) of < 4.0 mg/dL. Subjects with other curatively treated malignancies who have no evidence of metastatic disease and >2 year disease free interval may be entered after discussion with the Medical Monitor.
  • History of bleeding disorders, particularly coughing up ≥ ½ teaspoon bright red blood during the last 3 months
  • Certain cardiac disorders such as recent myocardial infarction (MI), severe congestive heart failure, certain types of abnormal cardiac rhythm
  • Uncontrolled high blood pressure despite medications
  • Uncontrolled, clinically significant active infection.
  • Known HIV
  • Known hypersensitivity to any of the components of CA4P, paclitaxel, carboplatin, bevacizumab, or radiologic contrast dyes.

Details of the above and additional inclusion and exclusion criteria can be discussed with an investigator.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00653939

United States, California
Southbay Oncology Hematology
Campbell, California, United States, 95008
Pacific Coast Hematology and Oncology Medical Group
Fountain Valley, California, United States, 92708
UCLA Division of Hematology and Oncology
Los Angeles, California, United States, 90095
Bay Area Cancer Research Group, LLC
Pleasant Hill, California, United States, 94523
United States, Kentucky
Kentuckiana Cancer Institute
Louisville, Kentucky, United States, 40202
United States, Massachusetts
Lahey Clinic Medical Center
Burlington, Massachusetts, United States, 01805
United States, New Jersey
The Center for Cancer and Hematologic Disease
Cherry Hill, New Jersey, United States, 08003
United States, New Mexico
San Juan Oncology Associates
Farmington, New Mexico, United States, 87401
United States, Ohio
Gabrail Cancer Center
Canton, Ohio, United States, 44718
The Mark H. Zangmeister Center
Columbus, Ohio, United States, 43219
Signal Point Clinical Research
Middletown, Ohio, United States, 45042
United States, Virginia
Blueridge Cancer Care
Salem, Virginia, United States, 24153
United States, Washington
Northwest Medical Specialties
Tacoma, Washington, United States, 98405
United States, West Virginia
Mary Babb Randolph Cancer Center-Clinical Trials Unit
Morgantown, West Virginia, United States, 26506
Sponsors and Collaborators
Study Director: Jai Balkissoon, MD OXiGENE
  More Information

Responsible Party: OXiGENE Identifier: NCT00653939     History of Changes
Other Study ID Numbers: OXC401-216
Study First Received: March 18, 2008
Last Updated: April 4, 2014
Health Authority: United States: Food and Drug Administration
India: Drugs Controller General of India

Keywords provided by OXiGENE:
non-small cell lung cancer
non-small cell lung carcinoma
neoplasms, lung
lung cancer

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Bronchial Neoplasms
Carcinoma, Bronchogenic
Lung Diseases
Neoplasms by Site
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Growth Inhibitors
Growth Substances
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Tubulin Modulators processed this record on November 25, 2014